Acne Medicine | Contrive Datum Insights

The Global Acne Medicine Market size was valued at USD 6.1 billion in 2022 and is projected to reach USD 10.8 billion by 2030, growing at a CAGR of 7.40% from 2022 to 2030.

Acne Medicine Market Overview:

The market is expected to exhibit moderate growth during the forecast period, which can be attributed to factors such as the emergence of lifestyle trends, unhealthy lifestyles, and increased morbidity.
Acne is a common dermatological condition, affecting more than 9.4 million people worldwide. Improper hormone production is the main reason. An increase in androgen (estrogen, in women) during puberty causes the onset of this condition by increasing the oil glands under the skin. This leads to excessive sebum production, which breaks down cell walls and pores leading to bacterial invasion. Although some studies show that the risk of developing acne can be increased due to genetics, some factors such as emotional stress, menstruation, hot weather and humidity, and bright jewelry can trigger mood.     

In this study, the global Acne Medicine Market is broken up into many different parts. For each product type, use, and player, regional market numbers are also given. We took into account the effects of COVID-19 and the war between Russia and Ukraine when working out how big the market. A Look at the Market for Acne Medicines: Over the next few years, the market is likely to grow slowly. This is happening because of things like new living trends, unhealthy lifestyles, and more people getting sick.

Key Market Updates:

• In January 2022, Procter & Gamble announced the strategic acquisition of Tula Skincare, which will add the brand's wellness to its rapidly growing portfolio of prestige products, including SK-II, First Aid Beauty, Ouai Hair Care, and Farmacy Beauty.
• In November 2022, Murad Inc., a subsidiary of Unilever, launched a lineup of skincare supplement products for acne and anti-aging. These products include vegan, rejuvenating, bright + even, clear skin in gel capsules that are clinically proven for health.
• In September 2022, Beiersdorf's renowned brand, NIVEA MEN, extends its successful global partnership with Real Madrid for three more seasons, until 2025. This collaboration will strengthen our focus on digital initiatives to reach younger consumers.

Major Market Segments Covered in Acne Medicine Market Industry Research:

• Allergan
• Nestle (Galderma)
• Johnson & Johnson
• Mayne Pharma
• Mylan
• Pfizer
• Vyome Biosciences
• Foamix Pharmaceuticals
• Valeant Pharmaceuticals
• BioPharm
• Others.

Key Vendors:

1.Allergan:It is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

2.Nestle (Galderma): Galderma is the leading company solely dedicated to skin and advancing the future of dermatology. We deliver an innovative, science-based portfolio of sophisticated brands and services across Aesthetics, Consumer Care and Prescription Medicine. Through trusted partnerships with healthcare professionals, we ensure to meet individual consumer and patient needs with superior outcomes.

3.Mayne Pharma: Mayne Pharma is an ASX-listed specialty pharmaceutical Company (ASX: MYX) focused on commercializing novel and generic pharmaceuticals. We offer patients better, safe and more accessible medicines.It is specialized in drug delivery technologies, pharmaceutical products, product development services, and contract manufacturing.

4.Vyome Biosciences: It is a 100% subsidiary of Vyome Therapeutics Inc (VTI) focused ondrug discovery and development services in the field of dermatology advancing the product pipeline of its parent company, VTI. VTL has a team of scientific and management experts with successful track record in the space of innovation and is currently prociding services to build VTI's robust pipeline of products. 

5.Foamix Pharmaceuticals: A clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea. It is Specialties in a Formulation, Topical, Dermatology, Foam, Skin, Psoriasis, Atopic Dermatitis, Acne, Rosacea, and Wound.

By Type:

• Prescription Medicine
• Over-the-counter (OTC) Medicine
• Other

By Route of Administration:

• Topical
• Oral
• Injectable
• Other

By Application:

• Inflammatory Acne
• Non-inflammatory Acne
• Other

By Region:

The North American market is expected to maintain the lion's share through 2030.

North America holds the largest share of the acne treatment market and is expected to continue to dominate over the forecast period. This is attributed to factors such as an unhealthy lifestyle including the diet of the urban population leading to the prevalence of acne in this region. For example, an estimated 50 million people in the United States suffered from acne in 2021, according to the 2022 American Academy of Dermatology (AAD). Also Bausch Health Companies Inc., Mylan N.V., Pfizer Inc., and Johnson & Johnson to further drive market growth in the region.

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Nordic Countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Union
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia-Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America

Significant Market Dynamics:

Dynamics:

• Growing awareness about skincare and personal grooming
• Rising prevalence of acne among the global population
• Increasing demand for cosmetic and dermatology treatments for acne
• Increasing investment in R&D activities for the development of new acne treatments
• Growing demand for topical and oral acne medications

Restraints:

• Side effects associated with acne medications
• High cost of treatment
• Availability of alternative therapies
• Stringent regulatory requirements for the approval of new acne medications

Trends:

• Growing popularity of natural and organic acne treatments
• Rising demand for personalized and customized acne treatments
• Increasing focus on combination therapies for acne treatment
• Growing adoption of advanced technologies for the diagnosis and treatment of acne

Drivers:

• Rising disposable income in developing countries
• Growing demand for acne medications among teenagers and young adults
• Increasing awareness about the benefits of early diagnosis and treatment of acne
• Rising prevalence of hormonal imbalances and lifestyle disorders

Challenges:

• Limited efficacy of existing acne medications
• High competition among market players
• Lack of standardization in the diagnosis and treatment of acne
• Poor patient adherence to treatment regimens

Opportunities:

• Development of new and innovative acne medications
• Growing demand for acne treatments in emerging markets
• Increasing adoption of e-commerce platforms for the sale of acne medications
• Rising demand for combination therapies for the treatment of moderate-to-severe acne.

Scope of report :